Nektar Therapeutics News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

31.12.19	Biotech Stocks Facing FDA Decision In January 2020 (RTTNews)
20.11.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
11.11.19	LPCN Awaits FDA Word, NKTR On Track, All's Well With Five Prime's FPT155 (RTTNews)
06.11.19	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
03.10.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
02.10.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
01.10.19	Nektar Therapeutics Promotes Gil Labrucherie To COO And CFO (RTTNews)
01.10.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
30.09.19	ÜBERBLICK/Anstehende Indexänderungen (Dow Jones)
27.09.19	INDEXÄNDERUNG/Las Vegas Sands steigt in S&P-500 auf (Dow Jones)
08.08.19	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
06.08.19	Ausblick: Nektar Therapeutics veröffentlicht Zahlen zum vergangenen Quartal (finanzen.net)
29.07.19	Biotech Stocks Facing FDA Decision In August 2019 (RTTNews)
08.05.19	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
06.05.19	Ausblick: Nektar Therapeutics stellt Ergebnisse des abgelaufenen Quartals vor (finanzen.net)
28.02.19	EARNINGS SUMMARY: Details of Nektar Therapeutics Q4 Earnings Report (RTTNews)
26.02.19	Ausblick: Nektar Therapeutics stellt Zahlen zum jüngsten Quartal vor (finanzen.net)
03.01.19	ImaginAb Reaches ImmunoOncology License&Clinical Trial Collaboration With Nektar (RTTNews)
07.11.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q3 Earnings Report (RTTNews)
06.11.18	Nektar Therapeutics And Pfizer Enter Into New Clinical Oncology Collaboration (RTTNews)
05.11.18	Ausblick: Nektar Therapeutics präsentiert Quartalsergebnisse (finanzen.net)
24.09.18	BioXcel Expands Collaboration With Nektar To Initiate New Clinical Program (RTTNews)
09.08.18	FDA Panel Nod For PRTK, INSY Settles With DOJ, Rite Aid Scraps Merger Deal (RTTNews)
08.08.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q2 Earnings Report (RTTNews)
31.07.18	LXRX On Watch, NKTR To Face FDA In May, TNDM Boosts Sales Outlook (RTTNews)
14.06.18	New Data for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to Opioid Therapy, Presented at College on Problems of Drug Dependence 80th... (PR Newswire)
05.06.18	Nektar to Webcast Presentation at the Jefferies 2018 Healthcare Conference in New York (PR Newswire)
03.06.18	Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018 (PR Newswire)
31.05.18	Nektar Therapeutics Announces Submission of a New Drug Application to the U.S. FDA for NKTR-181, a First-in-Class Investigational Opioid to Treat Chronic Low Back Pain in Adult Patients New to... (PR Newswire)
31.05.18	CRSP Falls On Clinical Hold, PFE Gets FDA Nod, ARWR To Report Data In Nov. (RTTNews)
30.05.18	Syndax and Nektar Therapeutics Announce Immuno-Oncology Clinical Trial Collaboration (PR Newswire)
17.05.18	FDA Thumbs-Down Makes EOLS Frown, IMMU Up On Breast Cancer Data, MGEN On Watch (RTTNews)
17.05.18	Nektar Therapeutics Announces Six Abstracts Accepted for Presentation at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting (PR Newswire)
10.05.18	EARNINGS SUMMARY: Details of Nektar Therapeutics Q1 Earnings Report (RTTNews)
10.05.18	Nektar Therapeutics Reports Financial Results for the First Quarter of 2018 (PR Newswire)
08.05.18	Nektar Therapeutics Announces Initiation of a Phase 1b Clinical Study of NKTR-358, a First-in-Class Regulatory T Cell Stimulator, in Patients with Systemic Lupus Erythematosus (PR Newswire)
03.05.18	Nektar to Announce Financial Results for the First Quarter 2018 on Thursday, May 10, 2018, After Close of U.S.-Based Financial Markets (PR Newswire)
30.04.18	Nektar Therapeutics to Host Analyst & Investor Event at 2018 ASCO Annual Meeting (PR Newswire)
24.04.18	Nektar Enters Into New Clinical Collaboration With Takeda (RTTNews)
24.04.18	New Oncology Clinical Collaboration between Nektar and Takeda to Evaluate Combination of NKTR-214, a CD122-biased Agonist, and TAK-659, a Dual SYK and FLT-3 Inhibitor, in Liquid and Solid Tumors (PR Newswire)
16.04.18	MÄRKTE USA/Freundlich - Vorschusslorbeeren für Quartalszahlen (Dow Jones)
16.04.18	Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting 2018 (PR Newswire)
11.04.18	Nektar Therapeutics Begins Dosing Patients In Phase 1/2 REVEAL Clinical Study (RTTNews)
11.04.18	Nektar Announces Dosing of First Patient in Phase 1/2 Clinical Study to Evaluate Combination of TLR Agonist NKTR-262 with CD122-Biased Agonist NKTR-214 in Patients with Advanced Solid Tumors (PR Newswire)
03.04.18	Nektar Therapeutics Announces Effective Date of Global Development & Commercialization Collaboration with Bristol-Myers Squibb (PR Newswire)
12.03.18	Nektar Therapeutics Turns Negative After Reaching Record High (RTTNews)
09.03.18	Take-Two Interactive Software, SVB Financial and Nektar Pharmaceuticals Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 (PR Newswire)
07.03.18	Nektar to Webcast Presentation at the Cowen and Company 38th Annual Health Care Conference in Boston (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

18.12.24		Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu
04.12.24		Freundlicher Handel: NASDAQ Composite am Mittag im Plus
03.12.24		Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen
27.11.24		Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge
22.11.24		Börse New York: NASDAQ Composite stärker
22.11.24		Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite
15.11.24		Schwacher Handel in New York: NASDAQ Composite verbucht zum Handelsende Abschläge
15.11.24		Zurückhaltung in New York: NASDAQ Composite verbucht nachmittags Verluste

18.12.24

Schwacher Handel in New York: NASDAQ Composite implodiert letztendlich nahezu

04.12.24

Freundlicher Handel: NASDAQ Composite am Mittag im Plus

03.12.24

Aufschläge in New York: NASDAQ Composite beendet den Handel mit Gewinnen

27.11.24

Handel in New York: NASDAQ Composite verbucht am Mittwochnachmittag Abschläge

22.11.24

Börse New York: NASDAQ Composite stärker

22.11.24

Starker Wochentag in New York: Zum Handelsstart Gewinne im NASDAQ Composite